Abstract
Materials and methods

Patient population selection
Study endpoints
The primary safety endpoint of the study was defined as a composite of MACE at 30 days defined as the incidence of cardiac death, Q-wave or non-Q-wave myocardial infarction, emergent cardiac surgery and clinically justified target lesion revascularisation (TLR) within 30 days following the index procedure. A TLR/TVR was considered clinically justified when the diameter stenosis was more than 50% (by off-line QCA) and either, (1) a history of recurrent angina pectoris presumably related to the target vessel, or (2) ischaemia-related ECG changes at rest or during exercise test related to the target vessel or either (3) an abnormal result of any invasive functional diagnostic test (including Doppler flow velocity reserve or fractional flow reserve). A TLR/TVR with
month clinical follow-up (non-hierarchical)
2 Non-cardiac death 4 TL re-PTCA, clinically justified 1 Cardiac death 2 TV re-PTCA, non-TLR, clinically justified 0 Q-wave MI 7 TL re-PTCA, non-clinically justified 0 Non Q-wave MI 3 TV re-PTCA, non-TLR, non-clinically justified 0 CABG 1 non-TVR re-PTCA 0 Stent thrombosis * One patient received no study stent because the delivery system could not cross the lesion. A non-study stent was implanted. 
